Prostate Cancer Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Prostate Cancer stocks.

Prostate Cancer Stocks Recent News

Date Stock Title
Nov 1 SNY Vir Biotechnology Inc (VIR) Q3 2024 Earnings Call Highlights: Strategic Restructuring and ...
Nov 1 SNY Kymera Q3 Loss Narrower Than Expected, Pipeline in Focus
Nov 1 LNTH Jim Cramer Likes Cava Group, Calls This Utilities Stock 'Terrific'
Nov 1 OPK Waters (WAT) Beats Q3 Earnings and Revenue Estimates
Nov 1 EXEL Exelixis, Inc. Just Recorded A 18% EPS Beat: Here's What Analysts Are Forecasting Next
Nov 1 AMGN Amgen Third Quarter 2024 Earnings: EPS Beats Expectations
Nov 1 LNTH Lantheus Holdings (LNTH) Achieves 22.5% Revenue Growth in Q2 2024
Nov 1 SNY Kymera Therapeutics Inc (KYMR) Q3 2024 Earnings Call Highlights: Strategic Advancements and ...
Oct 31 JAZZ Jazz Pharmaceuticals Presents New Data at Psych Congress 2024 Confirming Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution Treatment Benefits in Narcolepsy and Idiopathic Hypersomnia
Oct 31 AMGN Amgen earns higher revenues in Q3 2024, puts rare diseases in the spotlight
Oct 31 AMGN Q3 2024 Amgen Inc Earnings Call
Oct 31 AMGN Amgen 'Laser-Focused' On Its Weight-Loss Shot As New Rival Pfizer Follows, Says CFO
Oct 31 JAZZ Esperion Therapeutics (ESPR) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Oct 31 EXEL Exelixis: Cabometyx Drives Revenue While Zanzalintinib Emerges As Future Growth Engine
Oct 31 SNY REGN Q3 Earnings and Revenues Beat on Strong Eylea HD & Dupixent Sales
Oct 31 AMGN Amgen Q3 Earnings Beat, Sales In Line, Obesity Candidate in Focus
Oct 31 EXEL Exelixis price target raised to $36 from $33 at Piper Sandler
Oct 31 AMGN Amgen Inc (AMGN) Q3 2024 Earnings Call Highlights: Robust Revenue Growth and Strategic Pipeline ...
Oct 31 AMGN Amgen Inc. (AMGN) Q3 2024 Earnings Call Transcript
Oct 31 AMGN Amgen Inc. 2024 Q3 - Results - Earnings Call Presentation
Prostate Cancer

Prostate cancer is the development of cancer in the prostate, a gland in the male reproductive system. Most prostate cancers are slow growing; however, some grow relatively quickly. The cancer cells may spread from the prostate to other areas of the body, particularly the bones and lymph nodes. It may initially cause no symptoms. In later stages, it can lead to difficulty urinating, blood in the urine or pain in the pelvis, back, or when urinating. A disease known as benign prostatic hyperplasia may produce similar symptoms. Other late symptoms may include feeling tired due to low levels of red blood cells.Factors that increase the risk of prostate cancer include older age, a family history of the disease, and race. About 99% of cases occur in males over the age of 50. Having a first-degree relative with the disease increases the risk two to threefold. In the United States, it is more common in the African American population than the White American population. Other factors that may be involved include a diet high in processed meat, red meat or milk products or low in certain vegetables. An association with gonorrhea has been found, but a reason for this relationship has not been identified. An increased risk is associated with the BRCA mutations. Prostate cancer is diagnosed by biopsy. Medical imaging may then be done to determine if the cancer has spread to other parts of the body.Prostate cancer screening is controversial. Prostate-specific antigen (PSA) testing increases cancer detection, but it is controversial regarding whether it improves outcomes. Informed decision making is recommended when it comes to screening among those 55 to 69 years old. Testing, if carried out, is more reasonable in those with a longer life expectancy. While 5α-reductase inhibitors appear to decrease low-grade cancer risk, they do not affect high-grade cancer risk and thus are not recommended for prevention. Supplementation with vitamins or minerals does not appear to affect the risk.Many cases are managed with active surveillance or watchful waiting. Other treatments may include a combination of surgery, radiation therapy, hormone therapy or chemotherapy. When it only occurs inside the prostate, it may be curable. In those in whom the disease has spread to the bones, pain medications, bisphosphonates and targeted therapy, among others, may be useful. Outcomes depend on a person's age and other health problems as well as how aggressive and extensive the cancer is. Most men with prostate cancer do not end up dying from the disease. The 5-year survival rate in the United States is 99%. Globally, it is the second most common type of cancer and the fifth leading cause of cancer-related death in men. In 2012, it occurred in 1.1 million men and caused 307,000 deaths. It was the most common cancer in males in 84 countries, occurring more commonly in the developed world. Rates have been increasing in the developing world. Detection increased significantly in the 1980s and 1990s in many areas due to increased PSA testing. Studies of males who died from unrelated causes have found prostate cancer in 30% to 70% of those over age 60.

Browse All Tags